Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · IEX Real-Time Price · USD
21.48
-2.18 (-9.21%)
At close: Jul 2, 2024, 4:00 PM
21.01
-0.47 (-2.19%)
After-hours: Jul 2, 2024, 6:58 PM EDT
ARCT Revenue
Arcturus Therapeutics Holdings had revenue of $124.53M in the twelve months ending March 31, 2024, down -55.69% year-over-year. Revenue in the quarter ending March 31, 2024 was $38.01M, a -52.65% decrease year-over-year. In the year 2023, Arcturus Therapeutics Holdings had annual revenue of $166.80M, a decrease of -19.03%.
Revenue (ttm)
$124.53M
Revenue Growth
-55.69%
P/S Ratio
4.65
Revenue / Employee
$691,811
Employees
180
Market Cap
578.50M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 166.80M | -39.20M | -19.03% |
Dec 31, 2022 | 206.00M | 193.64M | 1,566.79% |
Dec 31, 2021 | 12.36M | 2.82M | 29.56% |
Dec 31, 2020 | 9.54M | -11.25M | -54.12% |
Dec 31, 2019 | 20.79M | 5.04M | 31.97% |
Dec 31, 2018 | 15.75M | 2.76M | 21.20% |
Dec 31, 2017 | 13.00M | -7.38M | -36.23% |
Dec 31, 2016 | 20.38M | 14.24M | 232.06% |
Dec 31, 2015 | 6.14M | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 2.00B |
Castle Biosciences | 250.73M |
SIGA Technologies | 157.02M |
IRadimed | 67.69M |
Zymeworks | 50.46M |
Arbutus Biopharma | 12.99M |
Lexicon Pharmaceuticals | 2.31M |
ARCT News
- 1 day ago - Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs - Business Wire
- 12 days ago - Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors - Business Wire
- 25 days ago - Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference - Business Wire
- 5 weeks ago - Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program - Business Wire
- 6 weeks ago - Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine - Business Wire
- 6 weeks ago - Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences - Business Wire
- 7 weeks ago - Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress - Business Wire
- 2 months ago - Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 - Business Wire